Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
1.
PLoS One ; 19(4): e0294329, 2024.
Article in English | MEDLINE | ID: mdl-38626043

ABSTRACT

As an essential material basis and power source for economic and social development, Western China's low energy use efficiency has hindered its sustainable economic development. This study aims to evaluate the total factor energy efficiency of the region and identify its influencing factors. A three-stage DEA model was used to measure the efficiency of 11 provinces from 2006 to 2021, and the Tobit model was employed to investigate internal factors. The findings show that (i) external environmental factors and stochastic perturbations have a significant impact on TFEE in the western region, overestimating integrated efficiency and scale efficiency and underestimating pure technical efficiency. (ii) the study of external influencing factors finds that the level of economic development increases input redundancy; the industrial structure increases capital input and labor input redundancy while decreasing energy input redundancy; and the energy consumption structure increases capital input and energy input redundancy while decreasing labor input redundancy. (iii) the study of internal influencing factors finds that the level of scientific and technological innovation, the level of openness to the outside world, and the TFEE have a positive correlation. In contrast, the intensity of environmental regulation has a negative correlation.


Subject(s)
Conservation of Energy Resources , Efficiency , Industry , Sustainable Development , Economic Development , China
2.
Sci Rep ; 14(1): 6788, 2024 03 21.
Article in English | MEDLINE | ID: mdl-38514745

ABSTRACT

This study aims to study the pro-environmental behaviour of herders in the Sanjiangyuan region, a significant ecological security barrier. This paper selected 212 herding households in the Sanjiangyuan area as research subjects by random sampling method. By establishing a multivariate ordered logistics model to study the impact of risk perception on herding households' pro-environmental behaviour and introducing capital endowment as a moderating variable to analyse the moderating effect of capital endowment on the relationship of herding households' risk perception-pro-environmental behaviour. The study results show that herders's risk perception significantly affects their pro-environmental behaviour, in which environmental risk perception, economic risk perception and disease risk perception positively affect their pro-environmental behaviour. Capital endowment has a moderating role in the relationship between risk perception and the pro-environmental behaviour of herding households. Accordingly, this paper proposes to strengthen publicity and education, encourage herders to join cooperatives, and improve the ability of risk perception and other countermeasures.


Subject(s)
Family Characteristics , Risk-Taking , Humans , Logistic Models , Perception , China
3.
Front Immunol ; 14: 1122629, 2023.
Article in English | MEDLINE | ID: mdl-36999036

ABSTRACT

Seizures are life-threatening complications of neuropsychiatric systemic lupus erythematosus (NPSLE) and are often associated with poor outcomes. Cyclophosphamide immunotherapy is the mainstay of NPSLE treatment. We report the unique case of a patient with NPSLE who developed seizures soon after her first and second doses of low-dose cyclophosphamide. The exact pathophysiological mechanism underlying cyclophosphamide-induced seizures is not well understood. However, this unusual drug-associated side effect of cyclophosphamide is thought to be due to the drug's unique pharmacology. Clinicians should be aware of this complication to make a correct diagnosis and adjust the immunosuppressive regimens very carefully.


Subject(s)
Lupus Erythematosus, Systemic , Lupus Vasculitis, Central Nervous System , Humans , Female , Lupus Vasculitis, Central Nervous System/diagnosis , Lupus Vasculitis, Central Nervous System/drug therapy , Lupus Erythematosus, Systemic/complications , Lupus Erythematosus, Systemic/diagnosis , Lupus Erythematosus, Systemic/drug therapy , Cyclophosphamide/adverse effects , Seizures/chemically induced , Seizures/drug therapy , Immunosuppressive Agents/adverse effects
4.
Front Immunol ; 12: 796865, 2021.
Article in English | MEDLINE | ID: mdl-34925383

ABSTRACT

Besides its contribution to the development of rheumatic diseases, the gut microbiota interact with anti-rheumatic drugs. The intestinal microbiota can directly metabolize many drugs and indirectly change drug metabolism through a complex multi-dimensional interaction with the host, thus affecting individual response to drug therapy and adverse effects. The focus of the current review is to address recent advances and important progress in our understanding of how the gut microbiota interact with anti-rheumatic drugs and provide perspectives on promoting precision treatment, drug discovery, and better therapy for rheumatic diseases.


Subject(s)
Antirheumatic Agents/therapeutic use , Dysbiosis/immunology , Gastrointestinal Microbiome/immunology , Animals , Humans , Precision Medicine , Rheumatic Diseases/drug therapy
5.
Front Immunol ; 12: 686501, 2021.
Article in English | MEDLINE | ID: mdl-34335588

ABSTRACT

Systemic lupus erythematosus (SLE), often considered the prototype of autoimmune diseases, is characterized by over-activation of the autoimmune system with abnormal functions of innate and adaptive immune cells and the production of a large number of autoantibodies against nuclear components. Given the highly complex and heterogeneous nature of SLE, the pathogenesis of this disease remains incompletely understood and is presumed to involve both genetic and environmental factors. Currently, disturbance of the gut microbiota has emerged as a novel player involved in the pathogenesis of SLE. With in-depth research, the understanding of the intestinal bacteria-host interaction in SLE is much more comprehensive. Recent years have also seen an increase in metabolomics studies in SLE with the attempt to identify potential biomarkers for diagnosis or disease activity monitoring. An intricate relationship between gut microbiome changes and metabolic alterations could help explain the mechanisms by which gut bacteria play roles in the pathogenesis of SLE. Here, we review the role of microbiota dysbiosis in the aetiology of SLE and how intestinal microbiota interact with the host metabolism axis. A proposed treatment strategy for SLE based on gut microbiome (GM) regulation is also discussed in this review. Increasing our understanding of gut microbiota and their function in lupus will provide us with novel opportunities to develop effective and precise diagnostic strategies and to explore potential microbiota-based treatments for patients with lupus.


Subject(s)
Dysbiosis/microbiology , Gastrointestinal Microbiome , Lupus Erythematosus, Systemic/microbiology , Animals , Bacteria/pathogenicity , Disease Models, Animal , Humans , Lupus Erythematosus, Systemic/etiology , Lupus Erythematosus, Systemic/metabolism , Lupus Erythematosus, Systemic/therapy
6.
Front Endocrinol (Lausanne) ; 12: 633767, 2021.
Article in English | MEDLINE | ID: mdl-34025575

ABSTRACT

Background: Although hyperuricemia frequently associates with respiratory diseases, patients with severe coronavirus disease 2019 (COVID-19) and severe acute respiratory syndrome (SARS) can show marked hypouricemia. Previous studies on the association of serum uric acid with risk of adverse outcomes related to COVID-19 have produced contradictory results. The precise relationship between admission serum uric acid and adverse outcomes in hospitalized patients is unknown. Methods: Data of patients affected by laboratory-confirmed COVID-19 and admitted to Leishenshan Hospital were retrospectively analyzed. The primary outcome was composite and comprised events, such as intensive care unit (ICU) admission, mechanical ventilation, or mortality. Logistic regression analysis was performed to explore the association between serum concentrations of uric acid and the composite outcome, as well as each of its components. To determine the association between serum uric acid and in-hospital adverse outcomes, serum uric acid was also categorized by restricted cubic spline, and the 95% confidence interval (CI) was used to estimate odds ratios (OR). Results: The study cohort included 1854 patients (mean age, 58 years; 52% women). The overall mean ± SD of serum levels of uric acid was 308 ± 96 µmol/L. Among them, 95 patients were admitted to ICU, 75 patients received mechanical ventilation, and 38 died. In total, 114 patients reached composite end-points (have either ICU admission, mechanical ventilation or death) during hospitalization. Compared with a reference group with estimated baseline serum uric acid of 279-422 µmol/L, serum uric acid values ≥ 423 µmol/L were associated with an increased risk of composite outcome (OR, 2.60; 95% CI, 1.07- 6.29) and mechanical ventilation (OR, 3.01; 95% CI, 1.06- 8.51). Serum uric acid ≤ 278 µmol/L was associated with an increased risk of the composite outcome (OR, 2.07; 95% CI, 1.18- 3.65), ICU admission (OR, 2.18; 95% CI, 1.17- 4.05]), and mechanical ventilation (OR, 2.13; 95% CI, 1.06- 4.28), as assessed by multivariate analysis. Conclusions: This study shows that the association between admission serum uric acid and composite outcome of COVID-19 patients was U-shaped. In particular, we found that compared with baseline serum uric acid levels of 279-422 µmol/L, values ≥ 423 µmol/L were associated with an increased risk of composite outcome and mechanical ventilation, whereas levels ≤ 278 µmol/L associated with increased risk of composite outcome, ICU admission and mechanical ventilation.


Subject(s)
COVID-19/blood , Uric Acid/blood , Adult , Aged , COVID-19/mortality , COVID-19/therapy , Female , Hospital Mortality , Hospitalization , Humans , Intensive Care Units , Male , Middle Aged , Prognosis , Respiration, Artificial , Retrospective Studies , Survival Rate
7.
Int Ophthalmol ; 40(11): 3059-3065, 2020 Nov.
Article in English | MEDLINE | ID: mdl-32607949

ABSTRACT

PURPOSE: Primary Sjögren's syndrome (pSS) has been proven as a systemic autoimmune disorder (such as Sjogren's syndrome dry eye). This research aimed to evaluate potential treating effects of Iguratimod on pSS. METHODS: Fifty pSS patients were enrolled and randomly divided into Conventional group and Iguratimod group. Improvement in pSS was evaluated every 4 weeks. pSS disease activity was evaluated with European League Against Rheumatism (EULAR) Sjögren's syndrome disease activity index (ESSDAI). Symptoms were evaluated by determining EULAR Sjögren's syndrome patient-reported index (ESSPRI), platelet (PLT), IgG and Schirmer I test. Peripheral blood B cell molecules (CD135, IgD, CD38, CD20) and human B cell-activating factor-receptor (BAFF-R) were analyzed with flow cytometry. RESULTS: After treating for 12-weeks, pSS patients in Iguratimod and Conventional group showed a significant decrease in disease activity (ESSPRI, ESSDAI, PLT, IgG and Schirmer I test) comparing with baselines. Patients' ESSPRI (2.92 ± 0.19) and disease activity of ESSDAI (4.32 ± 0.29), PLT (95.64 ± 1.86), IgG (13.0 ± 0.45) and Schirmer I test (4.67 ± 0.31) in Iguratimod group were significantly lower compared to Conventional group (4.64 ± 0.15, 5.8 ± 2.08, 77.44 ± 1.41, 16.5 ± 0.44 and 2.25 ± 0.11) (p < 0.0001). Changes of ESSPRI, ESSDAI, PLT, IgG and Schirmer I test were remarkable observed between two groups (p < 0.001). Iguratimod and Conventional treatment demonstrated a significant reduction in total B cells in pSS patients compared with pre-treatment. The pSS patients from Iguratimod and Conventional group showed a significant decreased BAFF-R (61.82 ± 1.52, 74.07 ± 1.11) and CD38+IgD+ (48.08 ± 0.92, 62.66 ± 1.12) on B cells after treatment compared with baseline (92.26 ± 0.32, 91.53 ± 0.45, 84.39 ± 0.59, 85.04 ± 0.46) (p < 0.001). After treating 12 weeks, BAFF-R, CD38+IgD+ expression in Iguratimod group decreased significantly compared to Conventional group (p < 0.001). CONCLUSIONS: Iguratimod alleviated symptoms and mediated adaptive-immunity balance by suppressing BAFF-R positive B cell in pSS patients.


Subject(s)
Sjogren's Syndrome , Chromones , Humans , Severity of Illness Index , Sjogren's Syndrome/drug therapy , Sulfonamides
8.
Methods Mol Biol ; 2108: 181-196, 2020.
Article in English | MEDLINE | ID: mdl-31939181

ABSTRACT

Aptamers are short, single-stranded RNA or DNA sequences, which can bind to protein ligands with high affinity and specificity. Applications of aptamers are broad, ranging from drugs and drug delivery vehicles to biosensors. Tumor necrosis factor (TNF) is an inflammatory cytokine that plays a critical role in the pathogenesis of several autoimmune inflammatory diseases. Blocking TNF activity by monoclonal antibodies or TNF receptor fusion protein has been tremendously successful in treating these diseases. However, manufacturing these biological TNF inhibitors is expensive and a significant proportion of patients do not respond to TNF blockade. Here we describe selection of single-stranded DNA aptamers for TNF blockage, and their bioactivity in blocking TNF-mediated cytotoxicity in vitro. These TNF-binding aptamers have the potential to serve as alternatives to biological TNF inhibitors and to be used as in vivo probes for TNF detection.


Subject(s)
Aptamers, Nucleotide , DNA, Single-Stranded , SELEX Aptamer Technique , Tumor Necrosis Factor-alpha/genetics , Antibodies, Monoclonal/pharmacology , Biological Assay , Cytokines/metabolism , Inflammation Mediators/metabolism , Polymerase Chain Reaction/methods , Polymerase Chain Reaction/standards , Tumor Necrosis Factor-alpha/antagonists & inhibitors
9.
J Immunol Res ; 2019: 3560180, 2019.
Article in English | MEDLINE | ID: mdl-30944832

ABSTRACT

Nanotechnology has become a novel subject with impact in many research and technology areas. Nanoparticles (NPs), as a key component in nanotechnology, are widely used in many areas such as optical, magnetic, electrical, and mechanical engineering. The biomedical and pharmaceutical industries have embraced NPs as a viable drug delivery modality. As such, the potential for NP-induced cytotoxicity has emerged as a major concern for NP drug delivery systems. Thus, it is important to understand how NPs affect the innate immune system. As the most abundant myeloid cell type in innate immune responses, neutrophils are critical for concerns about potentially toxic side effects of NPs. When activated by innate immune stimuli, neutrophils may initiate NETosis to release neutrophil extracellular traps (NETs). Herein, we have reviewed the relationship between NPs and the induction of NETosis and release of NETs.


Subject(s)
Extracellular Traps/drug effects , Immunity, Innate/drug effects , Inflammation , Nanostructures/adverse effects , Neutrophils/immunology , Animals , Drug Delivery Systems , Humans , Metal Nanoparticles/adverse effects , Metal Nanoparticles/therapeutic use , Mice , Neutrophils/drug effects
10.
J Biomed Res ; 34(2): 86-93, 2019 Oct 24.
Article in English | MEDLINE | ID: mdl-32305962

ABSTRACT

Neutrophils are major innate immune effector cells for host defense and have been a topic of active research for their participation in the pathogenesis of autoimmune inflammatory diseases including rheumatoid arthritis (RA) due to recently discovered neutrophil extracellular trap (NET) formation. NET formation and other mechanisms leading to the release of neutrophil nuclear and cytoplasmic contents are implicated as a source of citrullinated antigens in RA. Further investigations are required to delineate what factors diverge neutrophils from host defense to autoimmune response in RA.

11.
Front Pharmacol ; 10: 1684, 2019.
Article in English | MEDLINE | ID: mdl-32116681

ABSTRACT

Acarose is an anti-diabetic drug and exhibits anti-arthritic effects. We hypothesized that acarbose influences the gut microbiota to affect the course of arthritis and tested this hypothesis in a collagen-induced arthritis (CIA) murine model. Acarbose in drinking water was administered via gastric gavage started prior to or at the time of CIA induction. Gut microbiota were evaluated with 16S rRNA gene sequencing from fecal pellets collected prior to arthritis induction, during onset of arthritis, and after treatment. Immune response was evaluated by measuring changes in T helper-17 (Th17) and T regulatory (Treg) cells in the spleen and intestine, as well as serum cytokine levels. Before induction of CIA, acarbose significantly reduced the incidence of arthritis and attenuated clinical severity of arthritis. The frequency of Th17 cells was significantly decreased in the intestinal lamina propria in acarbose treated mice. Mice that were treated with acarbose showed significantly increased CD4+CD25+Foxp3+ Treg cells with elevation of Helios and CCR6. A remarkable alteration in microbial community was observed in acarbose treated mice. Bacterial diversity and richness in mice with arthritis were significantly lower than those in acarbose treated groups. The frequency of Firmicutes was significantly reduced after arthritis onset but was restored after treatment with acarbose. The frequency of Lactobacillus, Anaeroplasma, Adlercreutzia, RF39 and Corynebacterium was significantly higher in control groups than in acarbose treated, while Oscillospira, Desulfovibrio and Ruminococcus enriched in acarbose treated group. Miglitol, another α-glucosidase inhibitor showed a similar but less potent anti-arthritic effect to that of acarbose. These data demonstrate that acarbose alleviated CIA through regulation of Th17/Treg cells in the intestinal mucosal immunity, which may have resulted from the impact of acarbose on gut microbial community. Inexpensive antidiabetic drugs with an excellent safety profile are potentially useful for managing rheumatoid arthritis.

12.
J Cell Biochem ; 120(3): 2897-2907, 2019 03.
Article in English | MEDLINE | ID: mdl-30500980

ABSTRACT

BACKGROUND: Expression of forkhead box (FOX) superfamily members has been shown to be decreased in cancer, which was linked to poor prognosis of patients. The aim of this study was to investigate the expression of a new FOX superfamily member, FOXS1, in gastric cancer, and the influence of FOXS1 overexpression on the tumorigenesis of gastric cancer cells. The underlying molecular mechanism was also investigated. MATERIALS AND METHODS: FOXS1 expression levels were firstly measured in 15 paired gastric cancer and peritumor tissue using quantitative polymerase chain reaction or immunohistochemistry. Secondly, FOXS1 overexpression models were established in two gastric cancer cell lines (SNU-216 and AGS) and FOXS1 knockdown model was established in SNU-638 gastric cancer cell line. Markers for cell proliferation, metastasis, cell cycle status, and wnt/ß-catenin pathway were evaluated. Influence of FOXS1 overexpression on tumorigenesis was further evaluated in xenograft model. RESULTS: Expression of FOXS1 was significantly decreased in gastric cancer tissue in both messenger RNA and protein levels, compared with peritumor tissue. Our results showed that compared to cell lines transfected with negative control, gastric cancer cell lines with FOXS1 overexpression showed suppressed cell proliferation, metastasis, and increased ratio of G0/G1 phase. Xenograft model also showed suppressed tumor growth in FOXS1 overexpression group. Epithelial-mesenchymal transition was also inhibited when FOXS1 was overexpressed, which was indicated by an increase of E-cadherin expression and decrease in vimentin expression. Further investigation showed that expression of ß-catenin was decreased, together with decreased expression in downstream signaling factors, c-Myc and cyclin-D1 in FOXS1 overexpression cell lines. On the other hand, knockdown of FOXS1 showed opposite trends in the changes of those markers for cell proliferation, metastasis, cell cycle status, and wnt/ß-catenin pathway, compared with FOXS1 overexpression. CONCLUSION: In conclusion, the present study showed that FOXS1 expression is downregulated in most GC cases in our cohort, and this loss of expression may promote cell proliferation and metastasis through upregulation of wnt/ß-catenin pathway.


Subject(s)
Down-Regulation , Forkhead Transcription Factors/genetics , Forkhead Transcription Factors/metabolism , Stomach Neoplasms/pathology , Wnt Signaling Pathway , Animals , Cell Line, Tumor , Cell Movement , Cell Proliferation , Epithelial-Mesenchymal Transition , Female , Gene Expression Regulation, Neoplastic , Humans , Male , Mice , Neoplasm Metastasis , Neoplasm Transplantation , Stomach Neoplasms/genetics , Stomach Neoplasms/metabolism , Up-Regulation , beta Catenin/genetics , beta Catenin/metabolism
13.
Int J Clin Exp Pathol ; 8(10): 13619-24, 2015.
Article in English | MEDLINE | ID: mdl-26722585

ABSTRACT

Behçet's disease (BD)-like syndrome is an extremely rare situation occurred after Mycobacterium tuberculosis infection and virus infection. We reported a 45-year-old woman who visited our hospital complaining of swollen left ankle, painful genital ulcer, redness in the left eye and skin rash on lower limbs. The patient had a history of pleural tuberculosis and had received anti-tuberculous therapy for one year. Her left cervical lymph node sample demonstrated tubercle bacilli DNA fragmentation. The diagnosis of tuberculous lymphadenitis and Behçet's disease (BD)-like syndrome were made. This patient's symptoms remitted following treatment with anti-tuberculous therapy. This case indicates that some microbial infection can trigger the onset of BD-like syndrome in genetically susceptible subjects. However, treatment strategy of BD-like syndrome secondary to infection is totally different from primary BD. The aim of this case report is to present our experience of the different clinical signs and treatment of BD-like syndrome to expedite its early diagnosis in future. Combination of clinical, radiological, immunophenotypic, pathological, and genetic data contribute to improving the rate of diagnosis.


Subject(s)
Behcet Syndrome/etiology , Mycobacterium tuberculosis/isolation & purification , Tuberculosis, Lymph Node/complications , Behcet Syndrome/pathology , Female , Humans , Middle Aged , Tuberculosis, Lymph Node/pathology
14.
Zhonghua Nei Ke Za Zhi ; 54(11): 927-30, 2015 Nov.
Article in Chinese | MEDLINE | ID: mdl-26759211

ABSTRACT

OBJECTIVE: To explore the characteristics of sleep disturbance and its related factors in patients with rheumatoid arthritis (RA). METHODS: A total of 71 patients with RA in Department of Rheumatology Huaxi Hospital have completed the following questionnaires, including Pittsburgh sleeping quality index (PSQI), visual analogue scale (VAS), disease activity score in 28 joints (DAS28), health assessment questionnaire(HAQ), hospital anxiety and depression scale (HADS), fatigue severity scale (FSS) and a self-designed general status questionnaire. RESULTS: The prevalence of sleep disturbance was 42.3% (30/71) in rheumatoid arthritis patients (68.4%). The scores of DAS28, VAS, PSQI, HAQ, FSS and HADS in patients with sleep disturbance were significantly higher than those in patients with good sleep, which were respectively 3.90±1.12 vs 2.92±1.92, (5.03±2.63) scores vs (2.41±1.84) scores, (10.87±2.42) scores vs (4.29±1.85) scores, 3.0(0.0,7.0) scores vs 2.0 (0.5, 4.0) scores, (39.17±14.02) scores vs (29.63±16.12) scores, (14.50±7.77) scores vs (9.49±6.57) scores (P<0.05 in all scales). According to the results of Pearson correlation analysis, PSQI had significantly positive correlation with DAS28 (r=0.462, P<0.01), VAS (r=0.556, P<0.01), HAQ (r=0.360, P<0.01), FSS (r=0.420, P<0.01) and HADS (r=0.447, P<0.01) respectively. The logistic regression analysis indicated that VAS was a predictor for poor sleep quality (P<0.01). The patients receiving biological agents had significantly (P<0.05) lower scores of DAS28 (2.86±1.39 vs 3.52±1.10), PSQI [(5.90±4.24) scores vs (8.53±3.78) scores], VAS (2.15±2.30 vs 4.05±2.46), HAQ [0.0 (0.0, 2.0) scores vs 3.0 (0.0, 6.0) scores] compared to those taking oral drugs. CONCLUSION: High prevalence of sleep disturbance in patients with RA is noted, which indirectly influences the activity of disease, quality of life, depression, fatigue and other physical and mental health. Biological agents can partly improve the sleep disturbance and functional status.


Subject(s)
Arthritis, Rheumatoid/complications , Sleep Wake Disorders/complications , Depression , Fatigue , Humans , Logistic Models , Mental Health , Prevalence , Quality of Life , Sleep , Surveys and Questionnaires , Visual Analog Scale
SELECTION OF CITATIONS
SEARCH DETAIL
...